{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T02:58:52Z","timestamp":1789786732788,"version":"4.0.1"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,2]]},"DOI":"10.1097\/hjh.0b013e32834069bd","type":"journal-article","created":{"date-parts":[[2010,11,16]],"date-time":"2010-11-16T05:49:21Z","timestamp":1289886561000},"page":"207-216","source":"Crossref","is-referenced-by-count":56,"title":["Effects of verapamil added-on trandolapril therapy in hypertensive type 2 diabetes patients with microalbuminuria: the BENEDICT-B randomized trial"],"prefix":"10.1097","volume":"29","author":[{"given":"Piero","family":"Ruggenenti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Fassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aneliya Parvanova","family":"Ilieva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilian Petrov","family":"Iliev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Chiurchiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Rubis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Gherardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogdan","family":"Ene-Iordache","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavio","family":"Gaspari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Perna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Cravedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Bossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Trevisan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Motterlini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Remuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-7-20210208","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1038\/sj.ki.5001729","article-title":"Time to abandon microalbuminuria?","volume":"70","author":"Ruggenenti","year":"2006","journal-title":"Kidney Int"},{"key":"R2-7-20210208","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1016\/S0140-6736(82)92450-3","article-title":"Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus","volume":"1","author":"Viberti","year":"1982","journal-title":"Lancet"},{"key":"R3-7-20210208","doi-asserted-by":"crossref","first-page":"577","DOI":"10.7326\/0003-4819-118-8-199304150-00001","article-title":"Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients","volume":"118","author":"Ravid","year":"1993","journal-title":"Ann Intern Med"},{"key":"R4-7-20210208","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0140-6736(99)12323-7","article-title":"Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy.","volume":"355","year":"2000","journal-title":"Lancet"},{"key":"R5-7-20210208","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1056\/NEJMoa011489","article-title":"The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes","volume":"345","author":"Parving","year":"2001","journal-title":"N Engl J Med"},{"key":"R6-7-20210208","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"R7-7-20210208","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"R8-7-20210208","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1038\/ki.1996.480","article-title":"Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy","volume":"50","author":"Bakris","year":"1996","journal-title":"Kidney Int"},{"key":"R9-7-20210208","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1046\/j.1523-1755.1998.00083.x","article-title":"Effects of an ACE inhibitor\/calcium antagonist combination on proteinuria in diabetic nephropathy","volume":"54","author":"Bakris","year":"1998","journal-title":"Kidney Int"},{"key":"R10-7-20210208","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/S0197-2456(03)00028-X","article-title":"BENEDICT): design and baseline characteristics.","volume":"24","year":"2003","journal-title":"Control Clin Trials"},{"key":"R11-7-20210208","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1056\/NEJMoa042167","article-title":"Preventing microalbuminuria in type 2 diabetes","volume":"351","author":"Ruggenenti","year":"2004","journal-title":"N Engl J Med"},{"key":"R12-7-20210208","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/S0140-6736(95)91747-0","article-title":"Prevention of diabetic renal disease with special reference to microalbuminuria","volume":"346","author":"Mogensen","year":"1995","journal-title":"Lancet"},{"key":"R13-7-20210208","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/00041552-199703000-00006","article-title":"The diagnosis of renal involvement in noninsulin-dependent diabetes mellitus","volume":"6","author":"Ruggenenti","year":"1997","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"R14-7-20210208","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4899-3115-3","article-title":"Modelling survival data in medical research","author":"Collett","year":"1994"},{"key":"R15-7-20210208","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.diabres.2005.02.019","article-title":"Renoprotective effect of diltiazem in hypertensive type 2 diabetic patients with persistent microalbuminuria despite ACE inhibitor treatment","volume":"70","author":"Perez-Maraver","year":"2005","journal-title":"Diabetes Res Clin Pract"},{"key":"R16-7-20210208","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1111\/j.1523-1755.2004.00620.x","article-title":"Differential effects of calcium antagonist subclasses on markers of nephropathy progression","volume":"65","author":"Bakris","year":"2004","journal-title":"Kidney Int"},{"key":"R17-7-20210208","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2165\/00003088-200241030-00005","article-title":"Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update","volume":"41","author":"Song","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"R18-7-20210208","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1161\/01.CIR.0000024416.33113.0A","article-title":"Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect","volume":"106","author":"Viberti","year":"2002","journal-title":"Circulation"},{"key":"R19-7-20210208","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1161\/01.HYP.0000154082.72286.2a","article-title":"Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study","volume":"45","author":"Ibsen","year":"2005","journal-title":"Hypertension"},{"key":"R20-7-20210208","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.2337\/db06-1646","article-title":"Reduction in microalbuminuria as an integrated indicator for renal and cardiovascular risk reduction in patients with type 2 diabetes","volume":"56","author":"Araki","year":"2007","journal-title":"Diabetes"},{"key":"R21-7-20210208","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1001\/jama.292.20.2495","article-title":"Trends in cardiovascular complications of diabetes","volume":"292","author":"Fox","year":"2004","journal-title":"JAMA"}],"container-title":["Journal of Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00004872-201102000-00007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:40:16Z","timestamp":1786041616000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00004872-201102000-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/hjh.0b013e32834069bd","relation":{},"ISSN":["0263-6352"],"issn-type":[{"value":"0263-6352","type":"print"}],"subject":[],"published":{"date-parts":[[2011,2]]}}}